Mira Pharmaceuticals (MIRA) Share-based Compensation (2022 - 2025)
Mira Pharmaceuticals (MIRA) posted Share-based Compensation of $4.6 million for Q4 2025, up 3547.18% sequentially from $124972.0 in Q3 2025, and up 733.6% YoY from $546781.0 in Q4 2024.
Mira Pharmaceuticals (MIRA) Share-based Compensation (2022 - 2025) Analysis & Trends
Mira Pharmaceuticals has reported Share-based Compensation for 4 years, with the latest figure at $4.6 million in Q4 2025.
- Quarterly Share-based Compensation rose 733.6% year-over-year to $4.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.8 million (up 212.74% YoY) and the FY2025 annual result came in at $6.3 million, up 228.67% from the prior year.
- Share-based Compensation climbed to $4.6 million in Q4 2025 per MIRA's latest filing, from $124972.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $4.6 million in Q4 2025 and troughed at $124972.0 in Q3 2025.
- A 4-year average of $853225.2 and a median of $500000.0 in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation surged 914.88% in 2023, then tumbled 75.01% in 2025.
- Over 4 years, Share-based Compensation stood at $147800.0 in 2022, then jumped by 44.66% to $213813.0 in 2023, then jumped by 155.73% to $546781.0 in 2024, then jumped by 733.6% to $4.6 million in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $4.6 million, $124972.0, and $400000.0 for Q4 2025, Q3 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 458.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 165.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 231.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 249.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Mira Pharmaceuticals | 18.47 Mn | 7.44 Mn | - | 4.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.56 Mn |
| Dec 31, 2025 | 4.56 Mn |
| Sep 30, 2025 | 124,972.00 |
| Sep 30, 2025 | 124,972.00 |
| Mar 31, 2025 | 400,000.00 |
| Mar 31, 2025 | 400,000.00 |
| Dec 31, 2024 | 546,781.00 |
| Dec 31, 2024 | 546,781.00 |
| Sep 30, 2024 | 500,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 604,803.00 |
| Jun 30, 2024 | 604,803.00 |
| Mar 31, 2024 | 500,210.00 |
| Mar 31, 2024 | 500,210.00 |
| Dec 31, 2023 | 213,813.00 |
| Dec 31, 2023 | 213,813.00 |
| Sep 30, 2023 | 1.50 Mn |
| Sep 30, 2023 | 1.50 Mn |
| Jun 30, 2023 | 1.70 Mn |
| Jun 30, 2023 | 1.70 Mn |